

Surrey & North West Sussex Area Prescribing Committee

Policy Statement	Vedolizumab for treating moderately to severely active ulcerative colitis
Policy No:	PCN 166-2015
Date of Issue	September 2015
Review Date:	<p><i>No review date will be assigned to any drugs or devices that are subject to a NICE Technology appraisal.</i></p> <p><i>The recommendation made by the APC (formerly PCN) will be reviewed when new published evidence becomes available OR there is new published national guidance e.g. NICE)</i></p>
<p>Recommendations: The PCN recommends Vedolizumab as a treatment option for moderately to severely active ulcerative colitis in adults, in line with NICE TA342, if it is considered the most suitable therapy for the individual.</p>	
<p>Key Considerations:</p> <ul style="list-style-type: none"> NICE TA 342 http://www.nice.org.uk/guidance/ta342/resources/guidancevedolizumab-for-treating-moderately-to-severely-active-ulcerative-colitis-pdf The Ulcerative Colitis Pathway has been updated to include Vedolizumab as a treatment option. 	
Date taken to Area Prescribing Committee	Virtual decision August/September 2015
Agreed by APC members	18th September 2015